Sign in
CompletedNo phase

Urine Interleukin-37 as a Biomarker of Mortality Risk in Patients With Sepsis

Key facts

Who runs it
Zhongnan Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
99 people enrolled
Started
23 Mar 2022
Ended
20 Mar 2024
Type of study
Observational
Record updated
8 May 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Age 18 years or older
  • Expected length of stay>24 hours in intensive care unit (ICU)
  • Sequential organ failure assessment (SOFA) score ≥ 2 on ICU admission with a suspicion of infection

Who cannot take part

  • anuria
  • ICU readmission in 28 days

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study aims to evaluate the efficacy of IL-37 as a biomarker to predict mortality risk in adults with sepsis.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
8 May 2024